Table of Contents Below
April 27, 2022
Dr. Felicity Keiper traces the Convention on Biological Diversity’s activities around synthetic biology broadly and gene drive technologies specifically. She reviews the history of decisions and describes where current considerations of these topics are and what issues remain unresolved.

00:00 Speaker Introduction (Hector Quemada, Ph.D)
01:10 Opening remarks
01:55 Agenda
02:51 Convention on Biological Diversity (CBD)
04:24 Subsidiary Agreements (treaty family)
05:11 CBD Biotech Regulation
07:18 Cartagena Protocol on Biosafety (CP)
11:19 CP: Risk Assessment Framework
12:36 Developments and Current Status
12:58 CBD: Synthetic Biology
14:40 New and Emerging Issues (NEI)
16:51 CBD: Synthetic Biology – Programmes of work
18:45 CBD: Synthetic Biology – No internationally agreed definition
20:53 CBD: Synthetic Biology – What has been resolved
21:41 Decisions by the CBD COP – 2010-2014
26:05 Decisions by the CBD COP – 2016
28:12 Decisions by the CBD COP – 2018
29:53 Decisions by the Cartegena Protocol COP-MOP – 2018
32:14 Context in which COP13 and COP14 took place.
33:59 Biosafety Clearing-House
34:56 What’s Next?
35:12 CBD: Status of the Biodiversity Conference
37:57 CBD COP15: Synthetic Biology
40:13 CP COP-MOP10:Risk Assessment
41:27 Post 2020 Global Biodiversity Framework – Manage Impacts of Biotechnology
43:06 International Union for the Conservation of Nature (IUCN)
45:15 Question and Answers